Uncategorised - European Medical Journal

Could Focal Treatment for Intermediate-Risk Prostate Cancer Improve Outcomes?

Researches show MRI-guided HIFU to deliver focal therapy could improve quality of life for patients with intermediate-risk prostate cancer…

The Value of Evidence-Based Medicine

In this week’s episode, Jonathan is joined by Uwe Gudat, Chief Medical Officer, Aretaeus Sàrl, Geneva, Switzerland.

Editor’s Pick: Impact of COVID-19 on Diagnostic Delay in Rare Disease

Rare diseases are individually rare but collectively common, with a combined prevalence of 3.5–5.9%. A common feature of many diseases is a substantial delay in patients receiving a correct diagnosis; this protracted path to diagnosis is termed ‘the diagnostic odyssey’.

Insights into Newly Diagnosed Multiple Myeloma Treatment Options

Novel trial results show a more effective treatment route for newly diagnosed multiple myeloma. Read now for more details…

Three-Cycle Chemotherapy Regimen for Chronic Lymphocytic Leukaemia

New research shows that a three-cycle regimen of chemotherapy is an effective first-line treatment for patients with CLL. Read more…

Key Insights from EULAR 2022: An Interdisciplinary Expert Roundtable Discussion

IME Rheumatology Webinar | Key Insights from EULAR 2022 - An Interdisciplinary Expert Roundtable Discussion

Watch our roundtable discussion to gain a deeper understanding of emerging data from the EULAR 2022 congress.

New AZ study reveals extent of CKD worldwide

Chronic kidney disease is present in one in 10 adults, according to a recent study by AstraZeneca. Read the article for more details.

Medac Satellite Symposium at EULAR - Methotrexate in Current Clinical Practice: Optimizing the Anchor Drug in RA Therapy

During the medac satellite symposium at the annual congress of the European Alliance of Associations for Rheumatology (EULAR) 2022, Prof….

EMJ Cardiology 10 [Supplement 2] 2022 Feature Image

Novel Targeted Compression for the Prevention of Implantable Cardioverter Defibrillator or Pacemaker Pocket Complications: Strategies to Avoid Haematoma and Minimise Risk of Infection

Implantable cardioverter defibrillators (ICDs), pacemakers, and cardiac resynchronisation therapy (CRT) devices are placed in a pocket…

Cardiovascular catalyst launched by Novartis

A new CVD initiative has been launched by Novartis UK to drive innovation and improve patient access to prevention solutions.